Oppenheimer Holdings, Inc. Analysts Give Trevena, Inc. (TRVN) a $5.00 Price Target
Trevena, Inc. (NASDAQ:TRVN) has been given a $5.00 price objective by stock analysts at Oppenheimer Holdings, Inc. in a research report issued to clients and investors on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer Holdings, Inc.’s target price points to a potential upside of 153.81% from the company’s current price.
A number of other research firms have also issued reports on TRVN. Zacks Investment Research lowered Trevena from a “hold” rating to a “sell” rating in a report on Wednesday, July 26th. HC Wainwright lowered their price target on Trevena from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Cowen and Company reissued a “buy” rating and set a $10.00 price target on shares of Trevena in a report on Friday, August 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $10.23.
Shares of Trevena (NASDAQ:TRVN) traded down 16.88% during mid-day trading on Thursday, reaching $1.97. The company’s stock had a trading volume of 3,936,648 shares. Trevena has a 52 week low of $1.84 and a 52 week high of $8.00. The stock’s market capitalization is $117.60 million. The company’s 50-day moving average is $2.49 and its 200-day moving average is $2.75.
Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.35). Equities analysts predict that Trevena will post ($1.41) EPS for the current year.
A number of large investors have recently made changes to their positions in TRVN. Teachers Advisors LLC lifted its position in Trevena by 6.2% in the fourth quarter. Teachers Advisors LLC now owns 77,523 shares of the biopharmaceutical company’s stock valued at $456,000 after purchasing an additional 4,505 shares during the period. Wells Fargo & Company MN lifted its position in Trevena by 38.4% in the first quarter. Wells Fargo & Company MN now owns 222,349 shares of the biopharmaceutical company’s stock valued at $817,000 after purchasing an additional 61,650 shares during the period. Bank of New York Mellon Corp lifted its position in Trevena by 40.4% in the first quarter. Bank of New York Mellon Corp now owns 231,553 shares of the biopharmaceutical company’s stock valued at $851,000 after purchasing an additional 66,577 shares during the period. SG Americas Securities LLC lifted its position in Trevena by 81.0% in the first quarter. SG Americas Securities LLC now owns 35,926 shares of the biopharmaceutical company’s stock valued at $132,000 after purchasing an additional 16,079 shares during the period. Finally, American International Group Inc. lifted its position in Trevena by 7.1% in the first quarter. American International Group Inc. now owns 27,541 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 1,816 shares during the period. Hedge funds and other institutional investors own 60.09% of the company’s stock.
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.